The cells present in the 350-mg oral form of Cellorgane 2G pass into the bloodstream through the chyliferous membranes; they contain protein structures which, upon being ingested by macrophages (phagocytosis), undergo chemical transformations which keep their molecular structures intact. The patient's body thus receives a load of macromolecules with a high revitalising potential, since, amongst other bioactive molecules, it receives DNA, RNA, albumin, nucleotides, amino acids, etc., which work like veritable "matrices" of new nucleotides. These act by fixing the amino acids of each protein of the donor to homologous structures in the receptor's tissues. This is what triggers regeneration reactions in diseased tissue. This involves a true correction of the cell physiopathology of the receptor organ, since it is proven that receptor cells have an increased ribosomal synthesis activity (in other words, they manufacture new RNA chains).
In the case of the presentation of Cellorgane 2G in 750-mg injectable form, the main active ingredients are absorbed directly into the bloodstream upon administration. This absorption takes place by simple diffusion, following the gradient which exists between the deposit of the main active ingredients and the plasma. There is a rapid speed of absorption, since the area of the capillary membranes which absorb the product is broad and these are very soluble in the interstitial fluid. The relatively large aqueous channels of the endothelial membrane allow a high rate of diffusion of these molecules, regardless of their liposolubility. Distribution is to all the body's tissues, but mainly to the liver (50%) where some amino acids are stored, after a first-step metabolism. Metabolites are eliminated through the urine and faeces.
More Information |
||
| » Cellorgane Multicomplex 2G » Clinical Information and Pharmacology » Indications » Analysis |
» Contraindications » Side Effects » Clinical Study » Mechanisms of Action |
» Pharmacokinetics » Bibliography » Exclusive For Doctors |